Journal
JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE
Volume 79, Issue 4, Pages 579-585Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/jurban/79.4.579
Keywords
hepatitis B; hepatitis C; substance use; surveillance
Funding
- NIDA NIH HHS [1R01DA08023, 1F31DA05680] Funding Source: Medline
- ODCDC CDC HHS [U62/CCU006260] Funding Source: Medline
Ask authors/readers for more resources
Although public health surveillance system data are widely used to describe the epidemiology of communicable disease, occurrence of hepatitis B and C virus (HBV and HCV, respectively) infections may be misrepresented by under-reporting in injection drug users (IDUs). This study was carried out to examine the relationsbip between HBV and HCV incidence and case-reporting of hepatitis B and C in Seattle ID Us. Names of participants, in a Seattle ID U cohort study who acquired HB V or HCV infection over a 12-month follow-up period were compared to a database of persons with acute hepatitis B and C reported to the health department surveillance unit over the same period. Of 2,208 ID Us enrolled in the cohort who completed a follow-up visit, 63/759 acquired HBV infection, 53/317 acquired HCV infection, and 3 subjects acquired both HBV and HCV. Of 113 cohort subjects who acquired HBV or HCV, only 2 (1.5%) cases were reported, both bad acute hepatitis B. The upper 95% confidence limit for case-reporting of hepatitis C in the-cohort was 5.7%, and for hepatitis 13, it was 7.5%. In this study, reporting of acute hepatitis in IDUs was extremely low, raising questions regarding the use of community surveillance data to estimate underlying incidence in that population group.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available